Guardant Reveal
Use
Guardant Reveal is a blood‑based, tissue‑free circulating tumor DNA (ctDNA) assay to detect minimal residual disease (MRD) and recurrence monitoring in early‑stage colorectal, breast, and lung cancers, and therapy response monitoring in advanced solid tumors. It provides early detection of disease presence and recurrence, enabling timely clinical decision‑making in post‑surgery surveillance and treatment response contexts.
Special Instructions
Orders for Guardant Reveal are processed via Guardant Health test kit and mobile phlebotomy or clinic collection; testing is performed at Guardant Health’s laboratory in the United States. Medicare coverage is available through Palmetto GBA for colorectal cancer surveillance. Support services include billing assistance, insurance verification, financial assistance programs, and paperless ordering and tracking through the Guardant provider portal.
Limitations
Analytical sensitivity is dependent on cfDNA concentration in patient samples, which can vary substantially. Limit of detection may be affected by low genomic equivalents per mL and biological noise such as clonal hematopoiesis. Performance varies by disease context and timing of sample collection relative to surgery or therapy; validation primarily in early‑stage colorectal cancer with extension to other tumor types; not FDA‑reviewed.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
20 mL blood (2 × 10 mL Streck tubes)
Minimum Volume
4 mL blood in each of two tubes
Container
Streck tubes
Collection Instructions
Collect whole blood in Streck tubes using Guardant kit; ship at ambient temperature.
Storage Instructions
Ship ambient; strict ambient temperature required during transport.